Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease
Blood pressure medications widely used in sickle cell care worsen anemia by impairing red blood cell production, suggesting hemoglobin monitoring should become routine practice.
RAASi medications — widely used to treat albuminuria in sickle cell disease — independently worsen anemia in SCD patients, reducing hemoglobin by ~0.5 g/dL, a clinically meaningful drop for patients who are already chronically anemic. Mechanistic studies in SCD mice confirm impaired erythroid colony formation from bone marrow rather than reduced erythropoietin, providing a testable pathway and suggesting hemoglobin monitoring should be standard practice when initiating RAASi in this population.
What the study was
- Study design
- Cross-sectional analysis + two longitudinal cohorts + preclinical mouse model
- Population
- Adults with sickle cell disease on RAASi; mouse models
- Sample size
- 658
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood
Why it surfaced
Counter-intuitive drug safety finding with direct and immediate clinical practice implications: RAASi are current standard-of-care for SCD nephropathy, but this multi-cohort study demonstrates they worsen anemia by ~0.5 g/dL — clinically significant for an already anemic population. Hematologists managing SCD should monitor Hgb when initiating or continuing RAASi. Published in Blood (highest-impact hematology journal).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.